Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud

Novo NordiskNovo Nordisk and IBM Watson Health today announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The agreement combines Novo Nordisk's deep understanding of diabetes with IBM's leadership in cognitive computing.

The companies will explore possibilities for improved diabetes care via insights from real-time, real-world evidence of Novo Nordisk diabetes treatments and devices. By harnessing the potential of the Watson Health Cloud, Novo Nordisk aims to further advance its offerings to people living with diabetes and their healthcare professionals.

Commenting on the agreement, Jakob Riis, executive vice president, Novo Nordisk said: "Working with ambitious partners like IBM Watson Health helps us explore the opportunities presented by an increasingly digitalised healthcare system. We aim to leverage our combined capabilities to improve the lives of people with diabetes by making the management of the condition more simple, effective and measurable."

IBM Watson is the first commercially available cognitive computing platform and represents a new era of computing. The platform, delivered through the cloud, processes vast amounts of big data to uncover patterns and insights, understands complex questions posed in natural language, proposes evidence-based answers, and learns from each interaction. The Watson Health Cloud is a development platform for health and wellness solutions.

"IBM is excited to work with Novo Nordisk, a global leader in diabetes, to help the company create new e-health solutions on the Watson Health Cloud - accessing cognitive computing to help personalise care," said Deborah DiSanzo, general manager of IBM Watson Health.

About Diabetes
The International Diabetes Federation (IDF) estimates that 415 million people have diabetes today - a figure that IDF estimates could rise to 642 million by 2040. Complications from poorly managed diabetes include cardiovascular disease, kidney disease, nerve damage and blindness. Diabetes and its complications account for 12% of global health expenditure ($673 billion US dollars).(1)

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

About IBM Watson Health
In April 2015, IBM launched IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily. The Watson Health Cloud allows this information to be de-identified, shared and combined with a dynamic and constantly growing aggregated set of data such as clinical, research and social health data.

1. International Diabetes Federation, IDF Atlas, 7th edition, 2015.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]